| Bid | 19 |
| Market Cap | 1.39B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.45 |
| PE Ratio (ttm) | -7.78 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 19.44 |
| Volume | 558,350 |
| Avg. Volume (20D) | 716,226 |
| Open | 19.62 |
| Previous Close | 19.47 |
| Day's Range | 18.63 - 19.76 |
| 52-Week Range | 16.67 - 33.63 |
| Beta | undefined |
About SDGR
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on...
Analyst Forecast
According to 10 analyst ratings, the average rating for SDGR stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 57.40% from the latest price.
Next Earnings Release
Analysts project revenue of $83.39M, reflecting a 12.50% YoY growth and earnings per share of -0.4, making a 25.00% increase YoY.
4 weeks ago · businesswire.com
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company's co...
2 months ago · https://thefly.com
Schrodinger price target raised to $28 from $27 at Goldman SachsGoldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving b...
2 months ago · businesswire.com
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR SymposiumNEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symp...